IPO

Concord Biotech Limited IPO

Mainboard

Pharmaceuticals

Listed On: Aug 18, 2023 at ₹ 900.05(NSE)

₹ 14820 /20 Shares

Check Allotment

04 Aug, 2023

Open Date

08 Aug, 2023

Close Date

11 Aug, 2023

Allotment Date

18 Aug, 2023

Listing Date
Price Summary

Last Closing

1,341.00 (80.97%)

52 Week High

2,451.70

52 Week Low

1,314.90

Last Update

19-Dec-2025 3:30 PM
Concord Biotech Limited IPO Issue Details
  • Issue Price ₹705-741 per equity share
  • Face Value ₹1 Per Equity Share
  • Issue Price Offer for Sale : 20,925,652 shares(aggregating up to ₹1,551.00 Cr)
  • Listing at BSE, NSE
  • List Price 900.05(NSE)
  • Listing Date 2023-08-18
  • Lead Manager Kotak Mahindra Capital Company Limited
    Citigroup Global Markets India Private Limited
    Jefferies India Private Limited
  • Registrar Link Intime India Private Limited
Concord Biotech Limited IPO Details
  • Retail Portion 35% (Number of Retail Applications: 3,66,024 Approx),
    (Number of S-HNI Applications : 3,735 Approx),
    (Number of B-HNI Applications : 7,470 Approx)
Concord Biotech Limited IPO Documents
DRHP
RHP
ANCHOR
Concord Biotech Limited IPO Details


The IPO of Concord Biotech Limited is priced at ₹705-741 per equity share, which has a face value of ₹1 Per Equity Share each, IPO bidding starts from Aug 4, 2023 and ends on Aug 8, 2023. The allotment for Concord Biotech Limited IPO will be finalized on Aug 11, 2023. Concord Biotech Limited IPO will be listed on BSE, NSE, with a tentative listing date fixed as Aug 18, 2023. The company shall list its equity shares on the BSE, NSE. Link Intime India Private Limited is the registrar of the issue.

The book-running lead manager for the IPO is/are Kotak Mahindra Capital Company Limited, Citigroup Global Markets India Private Limited, Jefferies India Private Limited.


The Concord Biotech Limited IPO sets its price band at 705-741 for each share. A single application for Concord Biotech Limited IPO must contain at least 20 shares.

Read More
Concord Biotech Limited IPO Subscription Analysis And Details
Retail
3.77x
QIB
67.67x
NII
16.99x
bNII
19.30x
sNII
12.36x
Total
24.86x
As on QIB NII
bNII   sNII 		Retail Employee Total
Shares Offered / Reserved 4,183,130 3,137,348
2,091,565    1,045,783 		7,320,479 10,000 14,650,957
Day 1 04-08-23 05:00 PM
0.01 x 1.01
0.96 x   1.11 x 		0.72 x 5.73 x 0.58 x
Day 2 07-08-23 05:00 PM
1.61 x 5.22
5.12 x   5.42 x 		2.26 x 15.68 x 2.72 x
Day 3 08-08-23 05:00 PM
67.67 x 16.99
19.30 x   12.36 x 		3.77 x 24.39 x 24.86 x
Total No of Applications
12,63,516
Subscription on the basis of Applications
3.45
Concord Biotech Limited Valuations
Earnings Per Share (EPS) ₹22.95/-
P/E Ratio 32.3
RoNW 20.06%
Net Asset Value (NAV) - As on 31.03.23 ₹123.3
Concord Biotech Limited Company Financials
In Crs.
In Cr.
31-Mar-23 31-Mar-22 31-Mar-21
Assets 1,513.98 1,312.80 1,182.55
Revenue 888.48 736.35 630.75
Profit After Tax 240.08 174.93 234.89
About Concord Biotech Limited Company

Concord Biotech Limited is an India-based R&D-driven biopharma company. The company is ranked among the leading global developers and manufacturers of select fermentation-based APIs across immunosuppressants and oncology in terms of market share, based on volume in 2022.

Concord Biotech has a Global presence. They are supplying their products to over 70 countries including the USA, India, Europe, and Japan.

The company manufactures Active Pharmaceutical Ingredients (API) through fermentation & semi-synthetic process and finished formulations. It started with a single product and has grown to become a wide-spectrum solution provider.

Concord manufactures fermentation and semi-synthetic-based products in therapeutic segments such as Immunosuppressants, Anti-bacterial, Oncology, Antifungals & others. This wide range of products has attracted customers across the globe. Concord also has a robust pipeline of products under development.

Read More
Concord Biotech Limited - Promoter(s)

Mr. Sudhir Vaid

Mr. Ankur Vaid

Pre Issue Share Holding : 44.08%

Post Issue Share Holding : 44.08%

Concord Biotech Limited IPO - Issue Objectives
1

Achieve the benefits of listing the Equity Shares on the Stock Exchanges.

2

Carry out the Offer for Sale of up to 20,925,652 Equity Shares by the Selling Shareholder.

Concord Biotech Limited IPO - Anchor Investors

Concord Biotech raises Rs 465 crore from anchor investors ahead of IPO.

The government of Singapore, Abu Dhabi Investment Authority, Government Pension Fund Global, Polar Capital Funds, HSBC Mutual Fund, WF Asian Reconnaissance Fund, Amundi Funds, The Prudential Assurance Company and Pinebridge Global Funds are the marquee investors that participated in the anchor book of the professionally-managed biotech firm.

Apart from that, Nippon Life, UTI Mutual Fund, DSP Mutual Fund, Franklin Mutual Fund, SBI Life Insurance, Motilal Oswal Mutual Fund, Edelweiss Trusteeship, Invesco India, Bandhan Mutual Fund, Aditya Birla Sun Life, Max Life Insurance and Tata AIA Life Insurance also invested in the company via anchor book.

Concord Biotech Limited IPO - Peers Comparison
P/B Ratio P/E Ratio RoNW Revenue(in Cr.)
Concord Biotech 6.01 32.3 20.06% 888
Divi's Lab 7.77 54.4 14.9% 7,768
Suven Pharma 7.25 30.6 25.2% 1,340
Laurus Labs 4.49 33.6 20.4% 5,386